Plasminogen activator inhibitor-1 and thrombin activable fibrinolysis inhibitor in patients with type 2 diabetes

被引：0
|
作者：
Blaszkowski, A. [1 ]
Galar, M. [1 ]
Sokolowski, J. [1 ]
Kloczko, J. [1 ]
机构：
[1] Med Univ Bialystok, Bialystok, Poland
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1329
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Al-Hamodi, Zaid
    Ismail, Ikram S.
    Saif-Ali, Riyadh
    Ahmed, Khaled A.
    Muniandy, Sekaran
    CARDIOVASCULAR DIABETOLOGY, 2011, 10
  • [32] Impact of Ethnicity on the Association of Plasminogen Activator Inhibitor-1 and Tissue Plasminogen Activator Polymorphisms with Type 2 Diabetes Mellitus
    Al-Hamodi, Z.
    Saif-Ali, R.
    Ismail, I. S.
    Poh, R.
    Ahmed, R. H.
    Muniandy, S.
    PUBLIC HEALTH GENOMICS, 2015, 18 : 30 - 30
  • [33] Plasminogen Activator Inhibitor-1 Inhibits Thrombin Activity in Vein Grafts
    Ji, Yan
    Strawn, Tammy L.
    Grunz, Elizabeth A.
    Fay, William P.
    CIRCULATION, 2010, 122 (21)
  • [34] Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia
    Chhikara, Aruna
    Sharma, Sunita
    Chandra, Jagdish
    Nangia, Anita
    INDIAN JOURNAL OF PEDIATRICS, 2017, 84 (01): : 25 - 30
  • [35] Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia
    Aruna Chhikara
    Sunita Sharma
    Jagdish Chandra
    Anita Nangia
    The Indian Journal of Pediatrics, 2017, 84 : 25 - 30
  • [36] Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels
    C. Erem
    I. Nuhoglu
    M. Yilmaz
    M. Kocak
    A. Demirel
    O. Ucuncu
    H. Onder Ersoz
    Journal of Endocrinological Investigation, 2009, 32 : 169 - 174
  • [37] Blood coagulation and fibrinolysis in patients with Cushing's syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels
    Erem, C.
    Nuhoglu, I.
    Yilmaz, M.
    Kocak, M.
    Demirel, A.
    Ucuncu, O.
    Ersoz, H. Onder
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (02): : 169 - 174
  • [38] THROMBIN AND PLASMIN GENERATION IN PATIENTS WITH PLASMINOGEN OR PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 DEFICIENCY
    Saes, J.
    HAEMATOLOGICA, 2019, 104 : 25 - 26
  • [39] Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
    Saes, Joline L.
    Schols, Saskia E. M.
    Betbadal, Kathleen F.
    van Geffen, Mark
    Verbeek-Knobbe, Kitty
    Gupta, Sweta
    Hardesty, Brandon M.
    Shapiro, Amy D.
    van Heerde, Waander L.
    HAEMOPHILIA, 2019, 25 (06) : 1073 - 1082
  • [40] Plasminogen activator inhibitor-1 is associated with coronary artery calcium in type 1 diabetes
    Pratte, Katherine A.
    Hokanson, John E.
    Eckel, Robert H.
    Snell-Bergeon, Janet K.
    Rewers, Marian J.
    DIABETES, 2006, 55 : A162 - A162
12345